Last $2.37 USD
Change Today -0.0099 / -0.42%
Volume 94.7K
SNTA On Other Exchanges
Symbol
Exchange
NASDAQ GM
Stuttgart
As of 11:45 AM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

synta pharmaceuticals corp (SNTA) Snapshot

Open
$2.38
Previous Close
$2.38
Day High
$2.41
Day Low
$2.33
52 Week High
03/4/14 - $6.60
52 Week Low
02/2/15 - $2.18
Market Cap
258.1M
Average Volume 10 Days
627.6K
EPS TTM
$-1.02
Shares Outstanding
108.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SYNTA PHARMACEUTICALS CORP (SNTA)

synta pharmaceuticals corp (SNTA) Related Businessweek News

No Related Businessweek News Found

synta pharmaceuticals corp (SNTA) Details

Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs for treating severe medical conditions, including cancer and chronic inflammatory diseases. The company has two drug candidates in clinical trials for treating multiple types of cancer and various drug candidates in the preclinical stage of development. Its lead drug candidate includes ganetespib, an Hsp90 inhibitor, which is in Phase III clinical trial for the treatment of non-small cell lung cancer; in Phase II clinical trial for patients with hormone receptor positive metastatic breast cancer; in Phase I clinical trial for the treatment of HER2 positive patients with metastatic breast cancer; in Phase II/III clinical trial for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome; and in Phase I/II trial of paclitaxel in combination with ganetespib in patients with platinum-resistant ovarian cancer. The company’s product pipeline also comprises Hsp90-inhibitor Drug Conjugate, a novel, proprietary small molecule cancer drug development program; and Elesclomol, a mitochondria-targeting agent that is in Phase 2 clinical trial for ovarian cancer. Its product pipeline in preclinical development stage for inflammatory diseases includes CRACM ion channel inhibitors for rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, allergy, transplant rejection, and other autoimmune diseases and inflammatory conditions; and IL-12/23 inhibitors for inflammatory and autoimmune diseases. Synta Pharmaceuticals Corp. was incorporated in 2000 and is based in Lexington, Massachusetts.

134 Employees
Last Reported Date: 03/11/14
Founded in 2000

synta pharmaceuticals corp (SNTA) Top Compensated Officers

Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $486.3K
Compensation as of Fiscal Year 2013.

synta pharmaceuticals corp (SNTA) Key Developments

Synta Pharmaceuticals Corp. Announces About 20% Reduction in Workforce

Synta Pharmaceuticals Corp. announced about 20% reduction in its workforce as part of a change in its operating model. The company expects to realize cost savings from the job cuts in 2015. On a cumulative basis, headcount has been reduced from 133 at the beginning of 2014 to 90 now. The company said it will continue to seek productivity improvements and increased operating efficiencies as the new operating model for the organization is put in place. That includes a consolidation of Synta's office and laboratory facilities in 2016.

Synta Pharmaceuticals Corp. Presents at 17th Annual BIO CEO & Investor Conference, Feb-10-2015 03:00 PM

Synta Pharmaceuticals Corp. Presents at 17th Annual BIO CEO & Investor Conference, Feb-10-2015 03:00 PM. Venue: The Waldorf Astoria, New York, New York, United States. Speakers: Anne Clem Whitaker, Chief Executive Officer, President and Director.

Synta Announces Presentation of Results from an Investigator-Sponsored Phase 1 Trial of Ganetespib in HER2+ Metastatic Breast Cancer

Synta Pharmaceuticals Corp. announced presentation of preliminary results from an investigator-sponsored phase 1 trial, designed to evaluate ganetespib in combination with paclitaxel and trastuzumab in women with HER2+ metastatic breast cancer (MBC) refractory to other HER2 inhibitors. The results are being presented during a poster session at the 2014 San Antonio Breast Cancer Symposium in San Antonio, Texas. The phase 1 trial, conducted by physicians at New York University Langone Medical Center and Memorial Sloan Kettering Cancer Center, enrolled six heavily pretreated patients who received prior to entering the trial a edian of 3.5 anti-HER2 treatments in the metastatic setting (range 3-4), including trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1). Of the five patients evaluable for efficacy, partial tumor response was observed in one patient who remains on study, and four patients achieved stable disease ranging in duration from 11 to 29 weeks. Median Progression Free Survival was 19.4 weeks and the observed Clinical Benefit Rate (proportion of patients achieving objective response or stable disease greater than 24 weeks) was 60%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNTA:US $2.37 USD -0.0099

SNTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SNTA.
View Industry Companies
 

Industry Analysis

SNTA

Industry Average

Valuation SNTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SYNTA PHARMACEUTICALS CORP, please visit www.syntapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.